X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
0
Europe
Canada
0
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
0
Details:
The agreement provides Provectus with the University’s PDAT medical device in combination with a formulation of the Company’s proprietary pharmaceutical-grade RB-PDT (rose bengal sodium), for treating bacterial, fungal, and parasitic (acanthamoeba) infections of the eye.
Lead Product(s): Rose Bengal Sodium,Difluprednate,Moxifloxacin
Therapeutic Area: Infections and Infectious Diseases Product Name: RB-PDT
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Provectus Biopharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 27, 2024
Details:
Dolutegravir is a HIV type 1 integrase inhibitor, which is being evaluated in combination with daily rifapentine-moxifloxacin plus isoniazid and pyrazinamide regimen for the treatment of HIV-associated tuberculosis.
Lead Product(s): Dolutegravir Sodium,Rifapentine,Moxifloxacin
Therapeutic Area: Infections and Infectious Diseases Product Name: Tivicay
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: ViiV Healthcare
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
